|
See related Elaprase inj information |
|
|
|
Manufacturer |
Genzyme |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Idursulfase |
|
Indications |
Treatment of Hunter syndrome (mucopolysaccharidosis II). |
|
Dosage |
0.5 mg/kg body wt IV infusion over 1-8 hr wkly. |
|
Special Precautions |
Anaphylactic & allergic reactions. Postpone administration in acute resp &/or febrile illness. Childn <5 yr, elderly. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Anaphylactic & allergic reactions, hypoxic episodes, headache, fever, rash, pruritus, erythema, urticaria, HTN, arthralgia.
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
ATC Classification |
A16AB09 - idursulfase ; Belongs to the class of enzymes. Used in the treatment of alimentary tract and metabolism problems. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Elaprase injection |
|
Elaprase 2 mg/1 mL x 3 mL |
|
|
|
Manufacturer: |
Genzyme |
|
Distributor: |
Hong Kong: DKSH
|
|
|
|
